tiprankstipranks
Mercator Medical SA (DE:MM2)
FRANKFURT:MM2
Germany Market
MM2
Mercator Medical SA
RESEARCH TOOLSreports

Mercator Medical SA (MM2) Ratios

0 Followers

Mercator Medical SA Ratios

DE:MM2's free cash flow for Q4 2025 was zł0.25. For the 2025 fiscal year, DE:MM2's free cash flow was decreased by zł and operating cash flow was zł>-0.01. See a summary of the company’s cash flow.
Ratios
TTM
Mar 26Mar 25Dec 23Dec 22
Liquidity Ratios
Current Ratio
 ― 5.09 6.55 7.46 11.63
Quick Ratio
 ― 3.12 4.34 5.51 8.22
Cash Ratio
 ― 1.44 1.27 2.77 3.73
Solvency Ratio
 ― 0.45 0.59 0.02 -2.22
Operating Cash Flow Ratio
 ― 0.62 -0.74 >-0.01 0.68
Short-Term Operating Cash Flow Coverage
 ― 12.35 -1.47K -0.58 193.33
Net Current Asset Value
zł ―zł 370.77Mzł 516.39Mzł 479.72Mzł 623.71M
Leverage Ratios
Debt-to-Assets Ratio
 ― 0.02 <0.01 <0.01 <0.01
Debt-to-Equity Ratio
 ― 0.03 <0.01 <0.01 <0.01
Debt-to-Capital Ratio
 ― 0.02 <0.01 <0.01 <0.01
Long-Term Debt-to-Capital Ratio
 ― 0.00 0.00 0.00 >-0.01
Financial Leverage Ratio
 ― 1.14 1.12 1.12 1.07
Debt Service Coverage Ratio
 ― 2.83 7.12 -71.88 -162.85
Interest Coverage Ratio
 ― -23.77 76.05 -104.71 -227.09
Debt to Market Cap
 ― 0.01 <0.01 <0.01 <0.01
Interest Debt Per Share
 ― 2.56 0.53 0.65 0.43
Net Debt to EBITDA
 ― -8.10 25.18 4.12 1.38
Profitability Margins
Gross Profit Margin
―19.09%26.00%21.92%16.28%
EBIT Margin
―-2.48%-4.33%-15.67%-34.26%
EBITDA Margin
―2.54%-0.87%-10.96%-29.45%
Operating Profit Margin
―-2.48%5.73%-18.57%-33.40%
Pretax Profit Margin
―4.95%7.71%-0.81%-34.32%
Net Profit Margin
―4.98%9.41%-4.19%-34.95%
Continuous Operations Profit Margin
―5.11%9.18%-4.87%-35.17%
Net Income Per EBT
―100.68%121.94%518.88%101.83%
EBT Per EBIT
―-199.79%134.59%4.35%102.76%
Return on Assets (ROA)
―2.78%4.89%-2.04%-17.51%
Return on Equity (ROE)
―3.16%5.50%-2.28%-18.80%
Return on Capital Employed (ROCE)
―-1.53%3.29%-9.82%-17.71%
Return on Invested Capital (ROIC)
―-1.52%3.28%-9.81%-17.70%
Return on Tangible Assets
―2.85%5.05%-2.11%-17.92%
Earnings Yield
―8.18%11.37%-4.95%-39.33%
Efficiency Ratios
Receivables Turnover
 ― 5.71 5.91 4.51 7.79
Payables Turnover
 ― 7.18 5.20 8.34 12.69
Inventory Turnover
 ― 2.40 1.87 2.91 2.22
Fixed Asset Turnover
 ― 1.67 1.75 1.84 1.90
Asset Turnover
 ― 0.56 0.52 0.49 0.50
Working Capital Turnover Ratio
 ― 1.22 1.04 0.82 0.76
Cash Conversion Cycle
 ― 165.20 186.63 162.66 182.55
Days of Sales Outstanding
 ― 63.91 61.78 80.99 46.83
Days of Inventory Outstanding
 ― 152.10 195.09 125.45 164.47
Days of Payables Outstanding
 ― 50.81 70.25 43.79 28.75
Operating Cycle
 ― 216.01 256.87 206.44 211.30
Cash Flow Ratios
Operating Cash Flow Per Share
 ― 6.54 -7.67 >-0.01 4.18
Free Cash Flow Per Share
 ― 1.01 -9.67 -4.09 -7.05
CapEx Per Share
 ― 5.52 1.99 4.08 11.22
Free Cash Flow to Operating Cash Flow
 ― 0.16 1.26 455.27 -1.69
Dividend Paid and CapEx Coverage Ratio
 ― 0.87 -3.85 >-0.01 0.37
Capital Expenditure Coverage Ratio
 ― 1.18 -3.85 >-0.01 0.37
Operating Cash Flow Coverage Ratio
 ― 2.62 -15.79 -0.02 12.03
Operating Cash Flow to Sales Ratio
 ― 0.11 -0.13 >-0.01 0.08
Free Cash Flow Yield
―2.68%-20.23%-9.84%-14.28%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 ― 12.23 8.79 -20.21 -2.54
Price-to-Sales (P/S) Ratio
 ― 0.61 0.83 0.85 0.89
Price-to-Book (P/B) Ratio
 ― 0.39 0.48 0.46 0.48
Price-to-Free Cash Flow (P/FCF) Ratio
 ― 37.36 -4.94 -10.16 -7.00
Price-to-Operating Cash Flow Ratio
 ― 5.80 -6.23 -4.62K 11.82
Price-to-Earnings Growth (PEG) Ratio
 ― -0.28 -0.02 0.23 0.02
Price-to-Fair Value
 ― 0.39 0.48 0.46 0.48
Enterprise Value Multiple
 ― 15.90 -70.13 -3.61 -1.64
Enterprise Value
 ― 231.53M 330.24M 185.81M 262.22M
EV to EBITDA
 ― 15.90 -70.13 -3.61 -1.64
EV to Sales
 ― 0.40 0.61 0.40 0.48
EV to Free Cash Flow
 ― 24.75 -3.64 -4.75 -3.81
EV to Operating Cash Flow
 ― 3.84 -4.58 -2.16K 6.43
Tangible Book Value Per Share
 ― 94.74 95.15 86.25 100.75
Shareholders’ Equity Per Share
 ― 98.07 98.87 89.95 103.24
Tax and Other Ratios
Effective Tax Rate
 ― -0.03 -0.19 -5.02 -0.02
Revenue Per Share
 ― 62.27 57.80 48.94 55.53
Net Income Per Share
 ― 3.10 5.44 -2.05 -19.41
Tax Burden
 ― 1.01 1.22 5.19 1.02
Interest Burden
 ― -2.00 -1.78 0.05 1.00
Research & Development to Revenue
 ― 0.00 0.00 0.00 0.00
SG&A to Revenue
 ― 0.21 0.24 0.00 0.11
Stock-Based Compensation to Revenue
 ― 0.00 0.00 0.00 0.00
Income Quality
 ― 2.11 -1.41 <0.01 -0.22
Currency in PLN